Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06177795 · ClinicalTrials.gov registry record · NA
Increasing Screening for Cancer Using EHR-Nudges
A NA study of Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 21,120
- Enrollment target
- 2
- Study locations
NCT06177795 is a NA study of Breast Cancer that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 21,120 participants, above the 2,786-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (658% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06177795, a NA study of Breast Cancer, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 21,120 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study, personalized nudges to clinicians and patients will be evaluated to help increase breast cancer screening rates in accordance with USPSTF guidelines among women with a primary care visit, with a particular emphasis on those at high risk for non-completion of cancer screening. In partnership with Penn Medicine (Penn) and Case Western Reserve University-University Hospitals (UH), two complementary, concurrent, 6-month, cluster-randomized, pragmatic trials will be conducted. Those assigned to the intervention arm will receive the following clinician and patient level nudge interventions: clinicians will receive a default pended order for a mammogram in the visit encounter in the EHR (Penn and UH), and patients will receive post-visit text message reminders to encourage them to schedule their mammogram (Penn). Patients identified as high risk for noncompletion will be individually randomized to receive an additional bidirectional text message nudge or the standard text messaging (Penn).
Conditions Studied
Interventions
- BEHAVIORAL Default pended order
- BEHAVIORAL Post-visit patient text messaging
- BEHAVIORAL High risk bidirectional post-visit text messaging
Study Locations (2)
Ohio
- Case Western Reserve University/University Hospitals - Cleveland
Pennsylvania
- University of Pennsylvania Health System - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21,120 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2025-04-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06177795
The ClinicalTrials.gov registry entry for NCT06177795 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21,120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,786-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (658% higher). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Default pended order is the first listed.
NCT06177795 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06177795 about?
NCT06177795 is a clinical study titled "Increasing Screening for Cancer Using EHR-Nudges". In this study, personalized nudges to clinicians and patients will be evaluated to help increase breast cancer screening rates in accordance with USPSTF guidelines among women with a primary care visit, with a particular emphasis on those at high risk for non-completion of cancer screening. In partn...
What is the current status of trial NCT06177795?
This trial is currently completed. It is a NA study. The enrollment target is 21,120 participants. The study started on 2023-12-18. Estimated completion is 2025-04-07.
What conditions does trial NCT06177795 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06177795?
The interventions under investigation include: Default pended order (BEHAVIORAL), Post-visit patient text messaging (BEHAVIORAL), High risk bidirectional post-visit text messaging (BEHAVIORAL).
Who is sponsoring clinical trial NCT06177795?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06177795 being conducted?
This trial has 2 study locations across Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.